Press Release Fda Accepts New Drug Application And Grants Priority Review For Tlx101 Cdx Pixclara® Brain Cancer Imaging Agent
Search Related Content
Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Press Release Fda Accepts New Drug Application And Grants Priority Review For Tlx101 Cdx Pixclara® Brain Cancer Imaging Agent is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.Search RobinsPost News & Noticias
FDA Grants Priority Review to Revuforj for Mutant NPM1 AML
Revuforj, a menin inhibitor, is under priority review for relapsed or refractory mutant NPM1 AML, with a target action date of October 25, 2025. The AUGMENT-101 trial demonstrated Revuforj's efficacy, ... Read More
FDA says it's hiring more than 1,000 new staffers, launches new comms program for review process
The FDA says it is hiring more than 1,000 new employees and rolling out a pilot communication program in efforts to speed up the review of new drugs. | The FDA is hiring more than 1,000 new employees ... Read More
Pressure On, Purpose Questioned as Second Round of FDA Priority Review Vouchers Revealed
Priority voucher awardees and regulators could feel pressure to “meet the moment” as FDA watchers question the intent and feasibility of the Commissioner’s National Priority Voucher program. Read More
FDA Accepts New Drug Application for Relacorilant in Ovarian Cancer
Relacorilant targets glucocorticoid receptor proteins, potentially redefining treatment for platinum-resistant ovarian cancer by inhibiting cancer cell proliferation. Clinical trials show relacorilant ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus